The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or augmenting …

Chemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity
and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients …

Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited
treatment options and very poor prognosis following progression after standard …

Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …

Background Several studies have shown the efficacy, tolerability, and ease of administration
of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-…

Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)–positive
early and advanced breast cancer. In the German Breast Group 26/Breast …

The risk of venous thromboembolism (VTE) is increased in cancer patients. To improve
prediction of VTE in cancer patients, we performed a prospective and observational cohort study …

… c, d, IL-17 and IFN-γ production by T cells primed with C. albicans in the absence or presence
of neutralizing antibodies to IL-1β, IL-12 or both. e, IL-17 and IFN-γ production by T cells …

Purpose Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable
efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in …

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK
inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, …